Preventive Effect of Bone Marrow Mononuclear Cell Transplantation on Acute Myocardial Infarction-Induced Heart Failure: A Meta-analysis of Randomized Controlled Trials

Hosseinpour, Alireza; Hosseinpour, Hamidreza; Attar, Armin

doi:10.1007/s10557-022-07359-3

Cited by 4 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is while stem-cell-based therapies go one step further and attempt to reverse the damage through the provision of fresh, functional cells (22). While early studies on this topic were not very promising ( 9), later meta-analyses showed that this therapy might be effective in certain populations (23,25,26,27,28,29,30). Hence, in the present study, we selected patients below 65 with an echocardiographic LVEF <40%, yielding promising results.…”

Section: Discussionmentioning

confidence: 99%

“…A Cochrane meta-analysis showed that treating AMI patients with a reduced LVEF with BM-MNCs effectively increases LVEF, yielding survival and functional bene ts in patients below 55 with an EF below 37% (31). On the other hand, two more recent meta-analyses found that while post-AMI therapy with BM-MNCs can decrease hospitalization for CHF and re-infarction, their effect on all-cause mortality and stroke rate is questionable (27,28). Another cell type is MSCs, which were about twice as effective as BM-MNCs in the TAC-HFT trial (21).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Once vs. Twice Intracoronary Injection of Allogeneic-Derived Mesenchymal Stromal Cells after Acute Myocardial Infarction: BOOSTER-TAHA7 Randomized Clinical Trial

Attar

Kouhanjani

Hessami

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Mesenchymal stromal cell (MSC) transplantation can improve the left ventricular ejection fraction (LVEF) after an acute myocardial infarction (AMI). Transplanted MSCs apparently exert a paracrine effect, which might be augmented if repeated doses are administered. This study aimed to compare the effects of single vs.double transplantation of Wharton’s jelly MSCs (WJ-MSCs) on LVEF post-AMI. Methods: We conducted a single-blind, randomized, multicenter trial. After 3-7 days of an AMI treated successfully by primary PCI, 70 patients younger than 65 with LVEF <40% on baseline echocardiography were randomized to receive conventional care, a single intracoronary infusion of WJ-MSCs, or a repeated infusion ten days later. The primary endpoint was the six-month LVEF improvement as per cardiac magnetic resonance (CMR) imaging. Results: The mean baseline EF measured by CMR was similar (~40%) in all three groups. By the end of the trial, while all patients experienced a rise in EF, the most significant change was seen in the repeated intervention group. Compared to the control group (n=25), single MSC transplantation (n=20) improved the EF by 4.54 ± 2%, and repeated intervention (n=20) did so by 7.45 ± 2% when measured by CMR imaging (P<0.001); when evaluated by echocardiography, these values were 6.71 ± 2.4 and 10.71 ± 2.5%, respectively (P<0.001). Conclusions: Intracoronary transplantation of WJ-MSCs 3-7 days after AMI in selected patients significantly improves LVEF, with the infusion of a booster dose ten days later augmenting this effect. Trial registration: Trial registration: Iranian Registry of Clinical Trials, IRCT20201116049408N1. Registered 20 Nov. 2020 - Retrospectively registered, https://en.irct.ir/trial/52357

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Effect of Once vs. Twice Intracoronary Injection of Allogeneic-Derived Mesenchymal Stromal Cells after Acute Myocardial Infarction: BOOSTER-TAHA7 Randomized Clinical Trial

Attar

Kouhanjani

Hessami

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Photobiomodulation and mesenchymal stem cell-conditioned medium for the repair of experimental critical-size defects

Bayat,

Asgari,

Abdollahifar

et al. 2024

Lasers Med Sci

View full text Add to dashboard Cite

Effect of once versus twice intracoronary injection of allogeneic-derived mesenchymal stromal cells after acute myocardial infarction: BOOSTER-TAHA7 randomized clinical trial

Attar,

Farjoud Kouhanjani,

Hessami

et al. 2023

Stem Cell Res Ther

Self Cite

View full text Add to dashboard Cite

Background Mesenchymal stromal cell (MSC) transplantation can improve the left ventricular ejection fraction (LVEF) after an acute myocardial infarction (AMI). Transplanted MSCs exert a paracrine effect, which might be augmented if repeated doses are administered. This study aimed to compare the effects of single versus double transplantation of Wharton’s jelly MSCs (WJ-MSCs) on LVEF post-AMI. Methods We conducted a single-blind, randomized, multicenter trial. After 3–7 days of an AMI treated successfully by primary PCI, 70 patients younger than 65 with LVEF < 40% on baseline echocardiography were randomized to receive conventional care, a single intracoronary infusion of WJ-MSCs, or a repeated infusion 10 days later. The primary endpoint was the 6-month LVEF improvement as per cardiac magnetic resonance (CMR) imaging. Results The mean baseline EF measured by CMR was similar (~ 40%) in all three groups. By the end of the trial, while all patients experienced a rise in EF, the most significant change was seen in the repeated intervention group. Compared to the control group (n = 25), single MSC transplantation (n = 20) improved the EF by 4.54 ± 2%, and repeated intervention (n = 20) did so by 7.45 ± 2% when measured by CMR imaging (P < 0.001); when evaluated by echocardiography, these values were 6.71 ± 2.4 and 10.71 ± 2.5%, respectively (P < 0.001). Conclusions Intracoronary transplantation of WJ-MSCs 3–7 days after AMI in selected patients significantly improves LVEF, with the infusion of a booster dose 10 days later augmenting this effect. Trial registration: Trial registration: Iranian Registry of Clinical Trials, IRCT20201116049408N1. Retrospectively Registered 20 Nov. 2020, https://en.irct.ir/trial/52357

show abstract

Preventive Effect of Bone Marrow Mononuclear Cell Transplantation on Acute Myocardial Infarction-Induced Heart Failure: A Meta-analysis of Randomized Controlled Trials

Cited by 4 publications

References 32 publications

Effect of Once vs. Twice Intracoronary Injection of Allogeneic-Derived Mesenchymal Stromal Cells after Acute Myocardial Infarction: BOOSTER-TAHA7 Randomized Clinical Trial

Effect of Once vs. Twice Intracoronary Injection of Allogeneic-Derived Mesenchymal Stromal Cells after Acute Myocardial Infarction: BOOSTER-TAHA7 Randomized Clinical Trial

Photobiomodulation and mesenchymal stem cell-conditioned medium for the repair of experimental critical-size defects

Effect of once versus twice intracoronary injection of allogeneic-derived mesenchymal stromal cells after acute myocardial infarction: BOOSTER-TAHA7 randomized clinical trial

Contact Info

Product

Resources

About